|
1
|
Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists?
|
Arthritis Care Res (Hoboken)
|
2012
|
1.46
|
|
2
|
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.
|
Ann Rheum Dis
|
2014
|
1.17
|
|
3
|
Autoimmune aspects of cytokine and anticytokine therapies.
|
Am J Med
|
2003
|
1.03
|
|
4
|
Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy.
|
Autoimmun Rev
|
2013
|
1.02
|
|
5
|
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy.
|
Clin Exp Rheumatol
|
2011
|
0.99
|
|
6
|
Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
|
Ann Rheum Dis
|
2007
|
0.95
|
|
7
|
Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis.
|
Joint Bone Spine
|
2007
|
0.94
|
|
8
|
Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage.
|
PLoS One
|
2012
|
0.92
|
|
9
|
Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis.
|
J Rheumatol
|
2005
|
0.92
|
|
10
|
Autoantibody production in anti-TNF-alpha-treated patients.
|
Ann N Y Acad Sci
|
2007
|
0.90
|
|
11
|
Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.
|
Virol J
|
2013
|
0.87
|
|
12
|
Application of a stochastic modeling to assess the evolution of tuberculous and non-tuberculous mycobacterial infection in patients treated with tumor necrosis factor inhibitors.
|
PLoS One
|
2013
|
0.86
|
|
13
|
Emerging role for NK cells in the pathogenesis of inflammatory arthropathies.
|
Autoimmun Rev
|
2011
|
0.85
|
|
14
|
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
|
Rheumatology (Oxford)
|
2010
|
0.85
|
|
15
|
Biomarkers of subclinical atherosclerosis in patients with autoimmune disorders.
|
Mediators Inflamm
|
2012
|
0.85
|
|
16
|
Anti-cyclic citrullinated peptide antibody determination in the synovial fluid of patients with rheumatoid arthritis: comment on the article by Caspi et al.
|
Arthritis Rheum
|
2006
|
0.81
|
|
17
|
Induction of remission in rheumatoid arthritis: criteria and opportunities.
|
Rheumatol Int
|
2008
|
0.79
|
|
18
|
Monitoring biological therapies in psoriatic arthritis.
|
J Rheumatol Suppl
|
2009
|
0.78
|
|
19
|
CX3CL1 and CX3CR1 expression in tertiary lymphoid structures in salivary gland infiltrates: fractalkine contribution to lymphoid neogenesis in Sjogren's syndrome.
|
Rheumatology (Oxford)
|
2013
|
0.77
|
|
20
|
Anti-carbonic anhydrase II antibodies in systemic sclerosis: association with lung involvement.
|
Autoimmunity
|
2003
|
0.76
|
|
21
|
Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al.
|
Arthritis Rheum
|
2008
|
0.75
|
|
22
|
Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion.
|
J Rheumatol
|
2011
|
0.75
|